Tous Actualités
Suivre
Abonner Isotechnika Inc.

Isotechnika Inc.

Advisory - Isotechnika to Announce Interim Three Month Data From Phase 2b Kidney Transplant Trial

Edmonton, Alberta (ots/PRNewswire)

Isotechnika Inc. will
announce interim three month data from its Phase  2b kidney
transplant trial for the Company's lead immunosuppressive drug,
ISA247 on Monday, May 7th at 6:00 a.m. ET/4:00 a.m. MT. The
management team  will provide a review of the Phase 2b kidney
transplant trial via a live  conference call on Monday, May 7th at
9:00 a.m. ET/7:00 a.m. MT. All  interested parties will be able to
access the live event (audio only)  through the Company's corporate
web site at www.isotechnika.com.
About Isotechnika
Edmonton-based Isotechnika Inc. is an international
biopharmaceutical  company focused on the discovery and development
of novel immunosuppressive  therapeutics that are safer than
currently available treatments.  Isotechnika looks to become the
leader in development of immunosuppressant  therapies.
Isotechnika's lead drug, ISA247, has successfully completed a
Phase 3  Canadian trial for the treatment of moderate to severe
psoriasis. ISA247 is  currently being investigated in a combined
Phase 3 European/Canadian  psoriasis trial and a Phase 2b North
American trial for the prevention of  kidney graft rejection. One of
our partners, Lux Biosciences, has received  permission from the Food
and Drug Administration to investigate ISA247 in  three separate
pivotal Phase 2/Phase 3 trials for the treatment of non- infectious
uveitis and as a maintenance therapy in uveitis.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can
be  found at www.isotechnika.com.
Partnerships
Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and  commercialize ISA247 for all transplant indications.
On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use  of ISA247 and TAFA93 specifically with drug eluting devices for
the non- systemic treatment of vascular, cardiovascular, target
vessel and tissue  disorders.
Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive  license to develop and commercialize conjugates consisting
of Cellgate's  patented transporter technology for the topical
delivery of ISA247 in  patients suffering from mild to moderate
psoriasis.
On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug,  ISA247 for the treatment and prophylaxis of all ophthalmic
diseases.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of  its products, the Company's expectations regarding the
issuance of  additional patents and the Company's ability to protect
its intellectual  property, involve known and unknown risks and
uncertainties, which could  cause the Company's actual results to
differ materially from those in the  forward looking statements. Such
risks and uncertainties include, among  others, the availability of
funds and resources to pursue research and  development projects, the
ability to economically manufacture its products,  the potential of
its products, the success and timely completion of  clinical studies
and trials, the Company's ability to successfully  commercialize its
products, the ability of the Company to defend its  patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of  others. Investors should consult the Company's quarterly
and annual filings  with the Canadian commissions for additional
information on risks and  uncertainties relating to the forward-
looking statements. Investors are  cautioned against placing undue
reliance on forward-looking statements.

Contact:

For further information: Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., Phone: +1-(780)-909-4661,
Fax: +1-(780)-484-4105, E-mail: sgillis-paulgaard@isotechnika.com

Plus de actualités: Isotechnika Inc.
Plus de actualités: Isotechnika Inc.
  • 03.05.2007 – 15:20

    Isotechnika Selected for Oral Presentation at the American Transplant Congress

    Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika today announced that the Company has been selected to give an oral presentation during the American Transplant Congress in San Francisco, California. An overview of the latest Phase 2b kidney transplant trial (PROMISE) results will be presented during an oral ...

  • 11.04.2007 – 15:09

    Isotechnika to Host Educational Symposium at the American Transplant Congress

    Edmonton, Alberta (ots/PRNewswire) - Isotechnika will host an evening educational symposium at the American Transplant Congress. The evening symposium titled "Unleashing the Power of CNi's" will take place on Saturday, May 5th at 7:30 p.m. at the San Francisco Marriott Hotel. The symposium will highlight the use of ISA247 for the prevention of transplant ...